R. Brenner

A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

G. Abou-Alfa, J. Harding, M. Lowery, 2017, Cancer.

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

A. Chen, Z. Stadler, M. Lowery, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

M. Berger, C. Iacobuzio-Donahue, S. Leach, 2018, Journal of the National Cancer Institute.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma

Laura H. Tang, A. Chen, Z. Stadler, 2018, Cancer.

A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.

A. Chen, Z. Stadler, M. Lowery, 2020, Journal of Clinical Oncology.